The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
- PMID: 23620577
- PMCID: PMC4190613
- DOI: 10.1182/blood-2013-03-490003
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Abstract
As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Comment in
-
Pricing Cancer Drugs: When Does Pricing Become Profiteering?AMA J Ethics. 2015 Aug 1;17(8):750-3. doi: 10.1001/journalofethics.2015.17.8.nlit1-1508. AMA J Ethics. 2015. PMID: 26270874 No abstract available.
References
-
- Red Book online database. Accessed February 20, 2013.
-
- Goozer M. Berkley, CA: University of California Press; 2004. The $800 Million Pill: The Truth Behind the Cost of New Drugs.
-
- Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345:e4348. - PubMed
-
- Vasella D. Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History. New York, NY: Harper Collins Publishers; 2003:15-18,126,160-163,171-181.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
